Tenax Therapeutics, Inc.
NASDAQ:TENX · NASDAQ Capital Market
+$0.10 today
Vol 2.05M · Avg 0.62M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-54.2%
avg -231.5%
ROIC
-58.1%
avg -203.6%
ROA
-50.5%
avg -147.7%
Analysis
ROA is currently the strongest return metric at -50.5% versus its period average of -147.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Christopher T. Giordano | Chief Executive Officer, President & Director | $813,633.00 | — | 51 | $450,000.00 | 2.62% |
Stuart Rich | Chief Medical Officer & Director | $490,217.00 | — | 76 | $250,000.00 | 1.45% |
Thomas A. McGauley | Principal Financial Officer & Principal Accounting Officer | $475,498.00 | — | 53 | $450,000.00 | 2.62% |
Doug Randall | Chief Business Officer | — | — | — | — | — |
Thomas R. Staab | Chief Financial Officer | — | — | 58 | $450,000.00 | 2.62% |
Timothy G. Healey | Chief Commercial Officer | — | — | 60 | — | — |
Douglas Hay | Executive Vice President of Regulatory Affairs | — | — | — | — | — |
So-Young Kim | Executive Vice President of Clinical Development & Strategy | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
13
$189,522.86
Sells
0
$0.00
Net Sentiment
+$189,522.86
Net buying
Most Active
Rich Stuart
5 transactions
1–10 of 13
Analysis
Insiders reported 13 buys worth $189,522.86 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $189,522.86. Rich Stuart was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -65.8% | +77.7% (15yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at -65.8% over three years. Forward estimates point to Revenue at +77.7% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Q32 Bio Inc.
NASDAQ:QTTB
$161.43M
AN2 Therapeutics, Inc.
NASDAQ:ANTX
$134.68M
Verrica Pharmaceuticals Inc.
NASDAQ:VRCA
$62.15M
SAB Biotherapeutics, Inc.
SABS
$37.92M
Boundless Bio, Inc.
BOLD
$31.90M
Minerva Neurosciences, Inc.
NERV
$29.44M
Pluri Inc.
PLUR
$19.78M
Plus Therapeutics, Inc.
PSTV
$10.19M
Jasper Therapeutics, Inc.
JSPR
$7.49M
NextCure, Inc.
NXTC
$5.47M
Who manages TENX?
Tenax Therapeutics, Inc. (TENX) lists 8 active executives. The top listed executive is Stuart Rich, Chief Medical Officer & Director.
Are TENX insiders buying or selling?
Recent insider activity shows net buying of $43.71M.
Explore More
Continue the stock analysis
Jump to another research area for this company.